14305 results for ""Pennsylvania+German"+ACS+study+'Socius'+open+access"

in 16.08 milliseconds.

• RA-Map Data Access Committee

  Dac EGAC00001001589

• RAAK Data Access Committee

  Dac EGAC00001001619

• Data Access Committee lung cohort

  Dac EGAC00001001633

• HGT1 cohort Data Access Commitee

  Dac EGAC00001001701

• DSRCT Data Access Committee

  Dac EGAC00001001728

• TKI-BTRP Data Access Committee

  Dac EGAC00001001778

• Asthma Remission Dataset Access Committee

  Dac EGAC00001001780

• TKI-BTRP Data Access Committee

  Dac EGAC00001001782

• Whole genome sequencing access committee

  Dac EGAC00001001816

• Data Access Commitee for ECA

  Dac EGAC00001001856

• Data access committee DMDMex dataset

  Dac EGAC00001001871

• Keratoconus MIPS Data Access Committee

  Dac EGAC00001001883

• IMpower133 Data Access Committee

  Dac EGAC00001001932

• HNSCC Data Access Commitee

  Dac EGAC00001001935

• TKI-BTRP Data Access Committee

  Dac EGAC00001001938

• Tumor Samples Data Access Committee

  Dac EGAC00001001976

• DMP Data Access Commitee

  Dac EGAC00001001996

• Termeer Center Data Access Committee

  Dac EGAC00001002015

• bladder cancer data access commitee

  Dac EGAC00001002016

• Pinggu Metagenomics Data Access Committee

  Dac EGAC00001002023

• Maastricht MIBS data access commitee

  Dac EGAC00001002029

• CRCINA Data Access Commitee

  Dac EGAC00001002045

• Extreme Phenotypes Data access commitee

  Dac EGAC00001002055

• Wits Data Access Committee

  Dac EGAC00001002087

• UKM, Data Access Committee

  Dac EGAC00001002105

• CCHT Data Access Commitee

  Dac EGAC00001002132

• Retinal Dystrophy Data Access Committee

  Dac EGAC00001002161

• Data Access Committee for EGAS00001005426

  Dac EGAC00001002194

• LU Hematogenomics Data Access Commitee

  Dac EGAC00001002196

• Varn Lab Data Access Committee

  Dac EGAC00001002214

• KIR imputation data access committee

  Dac EGAC00001002216

• CRMY team data access committee

  Dac EGAC00001002249

• Data Access Committee for cfMeDIP

  Dac EGAC00001002250

• Tumor Thrombus data access committee

  Dac EGAC00001002272

• LEBAO Data access committee

  Dac EGAC00001002280

• VHIR Data Access Committee

  Dac EGAC00001002332

• Australian Genomics Data Access Commitee

  Dac EGAC00001002300

• LU Hematogenomics Data Access Commitee

  Dac EGAC00001002348

• Medulloblastoma cfDNA Data Access Commitee

  Dac EGAC00001002368

• DIAMOND Prostate Data Access Commitee

  Dac EGAC00001002407

• Cancer Team Data Access Committee

  Dac EGAC00001002449

• Data access committee of IMPC

  Dac EGAC00001002468

• GINS3 RNAseq Data Access Committee

  Dac EGAC00001002540

• Data access committee for FL

  Dac EGAC00001002552

• Fudan University Data Access Committee

  Dac EGAC00001002611

• Smith Lab Data Access Committee

  Dac EGAC00001002615

• Walker Lab Data Access Committee

  Dac EGAC00001002621

• PBMC genotypes Data Access Commitee

  Dac EGAC00001002633

• Pitroda Lab Data Access Comittee

  Dac EGAC00001002650

• SI-NET Data Access Committee

  Dac EGAC00001002701

• Sputum Metagenome Data Access Committee

  Dac EGAC00001002757

• Spatial MI Data Access Commitee

  Dac EGAC00001002721

• VIB-UZL Data Access Committee

  Dac EGAC00001002724

• Fudan University Data Access Committee

  Dac EGAC00001002736

• UKM, Data Access Committee

  Dac EGAC00001002755

• HiFi Project Data Access Commitee

  Dac EGAC00001002803

• IDIBELL Access Commitee

  Dac EGAC00001002816

• IgAN-tGBM Data Access Commitee

  Dac EGAC00001002821

• ADPKD Data Access Commitee 1

  Dac EGAC00001002838

• ITER-HUNSC Data Access Committee

  Dac EGAC00001002839

• SCA3_RNA-Seq Data Access Committee

  Dac EGAC00001002840

• Cancer Team Data Access Committee

  Dac EGAC00001002891

• Celtic Fire Data Access Commitee

  Dac EGAC00001002918

• PGDx EGA Data Access Committee

  Dac EGAC00001002922

• KiCS Data Access Committee

  Dac EGAC00001002930

• KiCS Data Access Committee

  Dac EGAC00001002935

• KiCS Data Access Committee

  Dac EGAC00001002936

• Iberian Roma Data Access Commitee

  Dac EGAC00001002958

• CirDNA sWGS Data Access Commitee

  Dac EGAC00001002965

• Methylation Atlas Data Access Committee

  Dac EGAC00001002983

• UCLA WGS data access Committee

  Dac EGAC00001003012

• Clinical Research Data Access Commitee

  Dac EGAC00001003052

• OPTIMISTIC team Data Access Commitee

  Dac EGAC00001003066

• PDAC PDx Data Access Committee

  Dac EGAC00001003139

• LFS Data Access Committee

  Dac EGAC00001003154

• Ludwig Agora Data Access Committee

  Dac EGAC00001003160

• MRC Prion Unit Data Access Committee

  Dac EGAC01000000007

• Data Access Committee for EGAS00001007298

  Dac EGAC00001003422

• Dual ST dataset access committee

  Dac EGAC00001002635

• The AGGA Data Access Committee

  Dac EGAC00001003019

• Sarcoidosis Baseline Data Access Committee

  Dac EGAC00001003072

• Cerebral Palsy Data Access Commitee

  Dac EGAC00001003068

• Data Access Committee for EGAS00001007299

  Dac EGAC00001003268

• NeuroCoV Data Access Committee

  Dac EGAC00001002776

• Radarstudy Data Access Committee

  Dac EGAC00001003289

• Hubrecht Institute Data Access Commitee

  Dac EGAC00001003003

• SECRETO Oral Data Access Committee

  Dac EGAC00001003449

• Sottorivalab data access committee

  Dac EGAC00001003184

• DIPG THU Data Access Committee

  Dac EGAC00001002169

• EPIC Repeatability Data Access Committee

  Dac EGAC00001003201

• NSCLC Team Data Access Committee

  Dac EGAC00001002258

• DFCI cHL Data Access Commitee

  Dac EGAC00001003432

• Human Heart Data Access Committee

  Dac EGAC50000000413

• Beggs Lab Data Access Committee

  Dac EGAC00001001819

• Inform-Lynch-Syndrome-Access

  Dac EGAC00001003315

• EMBARCAM BC360 PROJECT Data Access Committee

  Dac EGAC00001003517

• Personalis, Inc. Data Access Committee

  Dac EGAC50000000325

• BIOCLOCK Data Access Committee

  Dac EGAC00001003573

• BIDMC Proteogenomics Data Access Committee

  Dac EGAC50000000386

• Resuscitation Outcomes Consortium (ROC) Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Ventricular Tachycardia (ALPS)(ROC-ALPS-BioLINCC)

  Accessing Data Please refer to “Authorized Access” below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP. Objective To compare the effects of amiodarone, lidocaine, and placebo on survival to hospital discharge after out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia. Background Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) are common causes of out-of-hospital cardiac arrest, but are considered the most responsive to shock and therefore the most treatable. Nonetheless, most defibrillation attempts do not result in sustained return of spontaneous circulation, and VF or VT may persist or recur after shock. There is also evidence that longer durations of VF or VT are associated with decreases in the likelihood of resuscitation. Amiodarone and lidocaine are commonly used to promote successful defibrillation of shock-refractory VF or VT and prevent recurrences. Previous trials have shown amiodarone to be more effective than placebo or lidocaine for return of spontaneous circulation and survival at hospital admittance. This study sought to further extend the research and examine whether amiodarone would improve survival to hospital discharge and neurologic outcomes, as compared to placebo or lidocaine. Participants 3,026 eligible participants were enrolled, with 974 assigned to amiodarone, 993 assigned to lidocaine, and 1,059 assigned to placebo. An additional 1,627 participants that received a study intervention, but did not meet eligibility criteria, were included in analysis of the intention-to-treat population. Design The study interventions (amiodarone, lidocaine, and saline) were packaged in indistinguishable sealed kits and randomly distributed in to Emergency Medical Services (EMS) providers in a 1:1:1 ratio, stratified by participating site and agency. Each kit contained three syringes, and each syringe held 3 ml of colorless fluid containing 150 mg of amiodarone, 60 mg of lidocaine, or normal saline. Participants with out-of-hospital cardiac arrest were treated in accordance with local EMS protocols, in compliance with American Heart Association (AHA) guidelines. If VF or VT persisted or recurred after one or more shocks, eligible participants received a vasopressor and the masked kit containing amiodarone, lidocaine, or placebo. Approximating current clinical practice, the initial dose consisted of two syringes administered by rapid bolus. If the estimated body weight of the patient was less than 100 lbs., then one syringe was used. If VF or VT persisted, standard resuscitation measures, additional shocks, and an additional syringe of the study drug were administered. At that point the trial interventions were completed and standard interventions for advanced life support were employed. Upon arrival at the hospital, providers were notified of the patient's enrollment in the trial and encouraged to provide usual care in accordance with AHA guidelines, including open-label amiodarone or lidocaine if necessary. Components of hospital care were monitored but not standardized by the trial protocol. Participants, providers, and trial personnel were blinded to the trial drug assignments, with the exception of treating physicians if emergency un-blinding was required for care. Data from pre-hospital patient care records, CPR process measures, and hospital medical records were collected. The primary outcome of the trial was survival to hospital discharge, and the secondary outcome was survival with favorable neurologic status at discharge, defined as a score on the modified Rankin scale of 3 or less. Conclusions Neither amiodarone nor lidocaine resulted in a significantly higher rate of survival to hospital discharge or favorable neurologic outcome, as compared to placebo, among participants with out-of-hospital cardiac arrest due to initial shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.

  Study phs003784